By targeting Bcl-2, Bcl-xl, and Bcl-w antiapoptotic proteins, ABT-737 can kill both neuroblastoma SH-SY5Y cells and GBM T98G cells [153]. This evidence concerns the gene BCL2 and glioblastoma.